M&A

M&A DEAL OF THE YEAR


This award recognises the teams and organisations who have executed a truly transformational and high value M&A deal for both the company and the wider industry. 

Qualifying criteria
 
- The lead company must be a European Life Science company
- Open to private, public companies, pharma, commercial leaders or big tech
- Deal must be an M&A deal NOT a license, partnership or alliance
- Deal to have completed in the period between 1 September 2018 and 1 September 2019

Judges will be paying particular attention to:

- Uniqueness or novelty of deal strategy / terms and structure
- Level of value creation / size of deal
- Strength of acquirers existing pipeline / synergy with existing portfolio
- Potential game / industry changing implications within next 12-months
- Post-deal performance
 
 
 
BUY TICKETS AND TABLES
 
 

2019 FINALISTS

 

Bracco Diagnostics and Blue Earth Diagnostics

Bracco Diagnostics and Blue Earth Diagnostics

Ipsen and Clementia Pharmaceuticals

Ipsen and Clementia Pharmaceuticals

Kiadis Pharma and Cytosen Therapeutics

Kiadis Pharma and Cytosen Therapeutics

Pfizer and Therachon

Pfizer and Therachon

Servier and Shire Oncology Business Unit

Servier and Shire Oncology Business Unit

Zambon and Breath Therapeutics

Zambon and Breath Therapeutics

BUY TICKETS AND TABLES